Scenarios that move AZN

AstraZeneca PLC Ordinary Shares

Scenarios that move AZN: 17 analyses, 4 positive, 13 negative.

  1. · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▼ · impact -40 · confidence low · horizon quarters
  2. · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -30 · confidence low · horizon quarters
  3. · HALO wins court order blocking Merck's European Keytruda SC — ▼ · impact -22 · confidence low · horizon quarters
  4. · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -30 · confidence low · horizon weeks
  5. · United Therapeutics stock rises 12.6% in trading — ▼ · impact -25 · confidence low · horizon quarters
  6. · UK 30-year gilt yields top 6% for first time since 1998 — ▼ · impact -50 · confidence low · horizon quarters
  7. · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -40 · confidence low · horizon quarters
  8. · Zymeworks updates 2026 guidance after Theravance acquisition — ▼ · impact -32 · confidence medium · horizon quarters
  9. · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -12 · confidence low · horizon quarters
  10. · Ionis reports positive late-stage results for two partnered drugs — ▲ · impact +62 · confidence medium · horizon immediate
  11. · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +50 · confidence low · horizon quarters
  12. · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▼ · impact -25 · confidence low · horizon quarters
  13. · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +27 · confidence low · horizon weeks
  14. · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▼ · impact -28 · confidence medium · horizon quarters
  15. · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▼ · impact -60 · confidence high · horizon immediate
  16. · ◇ What if… Magdalena Andersson becomes Sweden’s next prime minister — ▼ · impact -10 · confidence low · horizon quarters
  17. · Amgen shares fall after Novartis' Pelacarsen misses Phase III goal — ▲ · impact +25 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing